Imunon, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- IMNNImunon10Calm
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Running, no new patientsPhase 1/2130 patientsMain results: Jul 25, 2024 - IMNNImunon0Calm
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Signing up patientsPhase 3500 patientsMain results: Oct 31, 2032 - IMNNImunon0Calm
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Signing up patientsPhase 1/230 patientsMain results: Jun 30, 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
6 sales (6 not pre-planned) · 0 purchases
- Eylward SusanGeneral Counsel and Corp Sec · Aug 31, 2026Sold 2,525 sharesabout $4 thousand · not pre-planned
- Eylward SusanGeneral Counsel and Corp Sec · Aug 17, 2026Sold 2,449 sharesabout $4 thousand · not pre-planned
- Eylward SusanGeneral Counsel and Corp Sec · Aug 3, 2026Sold 2,541 sharesabout $4 thousand · not pre-planned
- Eylward SusanGeneral Counsel and Corp Sec · Jul 20, 2026Sold 2,150 sharesabout $4 thousand · not pre-planned
- Eylward SusanGeneral Counsel and Corp Sec · Jul 6, 2026Sold 920 sharesabout $2 thousand · not pre-planned
- Eylward SusanGeneral Counsel and Corp Sec · Jun 29, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Permission to sell new sharesPermission to sell new shares (S-1)Oct 27, 2026
- Other newsNews report (8-K)Oct 27, 2026
- Signed a major agreement; Shared information with investorsNews report (8-K)Oct 21, 2026
- Signed a major agreementNews report (8-K)Sep 29, 2026
- Quarterly reportQuarterly report (10-Q)Aug 11, 2026
- Shared quarterly results